<DOC>
	<DOCNO>NCT02821416</DOCNO>
	<brief_summary>This randomize , double-blind , parallel group , placebo-controlled study design evaluate effect fix 30 mg dose benralizumab administer subcutaneously every 4 week allergen-induced inflammation subject mild atopic asthma challenge inhaled allergen .</brief_summary>
	<brief_title>Study Evaluate Effect Benralizumab Allergen-Induced Inflammation Mild , Atopic Asthmatics</brief_title>
	<detailed_description>This randomize , double-blind , parallel group , placebo-controlled study evaluate effect fix 30 mg dose benralizumab administer subcutaneously every 4 week 3 dos allergen-induced inflammation subject mild atopic asthma challenge inhaled allergen . Approximately 38 non-smoking men woman ( 18 - 65 year age ) corticosteroid-free ( oral inhale ) mild , atopic asthmatic demonstrate dual ( early late ) asthmatic response inhale allergen challenge screen recruit complete study .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<criteria>1 . Provision inform consent prior study specific procedures 2 . Female male age 18 65 year , inclusively , time enrolment . 3 . General good health 4 . Mild , stable , allergic asthma asthma therapy limit inhaled , shortacting beta 2 agonist ( twice weekly ) 5 . Positive skinprick test least one common aeroallergen 1 . Current lung disease mild allergic asthma 2 . Any history symptom disease , include , limited , cardiovascular , neurologic , autoimmune haematologic 3 . Any clinically significant abnormal finding laboratory test result complete blood count , coagulation , chemistry panel urinalysis enrolment screen period 4 . History anaphylaxis biologic therapy vaccine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>asthma</keyword>
</DOC>